Partial Nephrectomy of Renal Cell Carcinoma From the Donor Allograft Prior to Living Donor Renal Transplantation

Cottrell-Cumber, Sarah; Panchal, Ramola; Wynn, James J.; Matemavi, Praise; Anderson, Christopher

doi:10.1177/00031348221083953

The American Surgeon™

2022

DOI: 10.1177/00031348221083953

|View full text |Cite

Partial Nephrectomy of Renal Cell Carcinoma From the Donor Allograft Prior to Living Donor Renal Transplantation

Sarah Cottrell-Cumber

Ramola Panchal

James J. Wynn

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Villani,

Kulkarni,

Fair

et al. 2024

Clinical Transplantation

View full text Add to dashboard Cite

BackgroundSmall malignant renal tumors can be found in up to 1.3% of kidney donors. Several studies have investigated the use of these kidneys for transplantation, after ex vivo resection of the malignant mass.MethodsWe performed a systematic review of the literature on PubMed, Embase, and Web of Science of studies including reports of malignant renal masses excised from kidney grafts prior to transplantation. Articles including benign pathology only were excluded.ResultsOur search strategy identified 226 patients over 32 studies. Pathology included 107 clear cell carcinomas, 27 papillary renal cell carcinomas (RCCs), 84 other types of RCCs, and 8 transitional cell carcinomas. The majority of cancers were grade 1 or 2 (81.6%). Average tumor size was 12.6 mm. Clavien–Dindo ≥ 3 complication rate was 22%. Mean follow‐up was 39.9 months. The 1‐year, 3‐year, and 5‐year overall survival rate for recipients of living donor grafts was 95.8%, 92.1%, and 75.1%. The 1‐year, 3‐year, and 5‐year living donor death‐censored graft survival rate was 90.8, 85.2%, and 64.8%. Of the 226 patients, 6 (2.7%) experienced a malignant recurrence. The average time to recurrence was 36.1 months.ConclusionsTransplantation of kidney grafts after resection of small cancerous masses is relatively safe and has low rates of recurrent malignancy. In the case of a living donor, appropriate counseling on partial nephrectomy versus donor nephrectomy should be provided, ideally by a surgeon who is not part of the transplant team. Recipients of these grafts should be carefully selected and counseled regarding the additional potential technical and oncological risks.

show abstract

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Villani,

Kulkarni,

Fair

et al. 2024

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Partial Nephrectomy of Renal Cell Carcinoma From the Donor Allograft Prior to Living Donor Renal Transplantation

Cited by 1 publication

References 4 publications

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Kidney Transplantation From Donors With Malignant Renal Masses: A Systematic Review

Contact Info

Product

Resources

About